New drug combo targets tough leukemia in early trial

NCT ID NCT05199051

Ongoing Disease control Sponsor: Centre Antoine Lacassagne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new combination of two drugs (gemtuzumab ozogamicin and gilteritinib) for adults with a specific genetic form of acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial aims to see if the combination is safe and helps control the disease. It includes 19 participants across multiple centers in France.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia acute myeloid leukemia, FLT3 internal tandem duplication acute myeloid leukemia, FLT3 tyrosine kinase domain point mutation childhood leukemia leukemia Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML LEUKAEMIA (ACUTE MYELOID)

Contacts and locations

Locations

CHMS de Chambery

Chambéry, France
CHRU Nancy

Nancy, France
CHU Bordeaux

Bordeaux, France
CHU Limoges

Limoges, France
CHU d'Amiens

Amiens, France
CHU d'Angers

Angers, France
CHU de Caen

Caen, France
Centre Henri Becquerel

Rouen, France
Centre Hospitalier Universitaire de Nice

Nice, France
Centre Hospitalier de Versailles

Versailles, France
HIA Percy

Clamart, France
Hôpital Saint Louis

Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.